



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 77-507

Food and Drug Administration  
Rockville MD 20857

OCT 27 2005

CorePharma LLC  
Attention: Mukteeshwar Gande, M.S., R.Ph.  
Vice President  
215 Wood Avenue  
Middlesex, NJ 08846

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated December 29, 2004, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Glipizide and Metformin Hydrochloride Tablets, 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg.

Reference is also made to your amendments dated June 27, June 28, July 27, August 29, September 1, and October 20, 2005.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Glipizide and Metformin Hydrochloride Tablets, 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Metaglip<sup>®</sup> Tablets 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg, respectively, of Bristol Myers Squibb Co.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Gary Buehler". The signature is fluid and cursive, with the first name "Gary" being more prominent.

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research